Zoetis' Reset Year: Pet-Care Weakness, Livestock Strength, and a New Finance Chief
Published on 08/11/2026 at 16:23 | Redaktion boerse-global.de
The animal-health giant's 2026 guidance reset has sent ripples through Wall Street, but the picture forming around Zoetis is more nuanced than a simple growth scare. While the companion-animal segment — long the company's growth engine — is buckling under competitive pressure, the livestock division is quietly doing heavy lifting, and a leadership shuffle at the finance helm adds another layer of complexity for investors to weigh.
A Guidance Cut That Reshaped the Year
The numbers tell a stark story. Zoetis now expects full-year revenue of $9.12 billion to $9.32 billion, a substantial pullback from the $9.68 billion to $9.96 billion range previously guided. Adjusted earnings per share took an even sharper hit, with the company now projecting $6.15 to $6.25, down from the earlier $6.85 to $7.00 outlook. Management pointed to deepening softness in the US pet-care market, noting that demand failed to stabilize in July.
The second-quarter results, covering the period through June 30, illustrate the shifting dynamics. Revenue came in at $2.47 billion, essentially flat and just shy of the $2.50 billion consensus. Adjusted EPS of $1.87 topped expectations by two cents, helped along by $550 million in share buybacks that trimmed the weighted diluted share count by 6.2% year over year to 417.7 million.
Divergent Fortunes Across Segments
The most striking contrast sits within the US business. Companion-animal revenue fell 11%, with the dermatology franchise suffering a 16% decline to $395 million as competition intensifies and customers grow increasingly price-sensitive. That weakness stands in sharp relief against the livestock segment, which surged 23% to $222 million — boosted in part by elevated demand for parasite treatments following an outbreak of New World screwworm.
Should investors sell immediately? Or is it worth buying Zoetis?
The company has been building on that livestock momentum operationally. Zoetis secured conditional FDA approval for a new parasite product targeting screwworm in cattle, and the needle-free Suvaxyn PRRS vaccine received EU approval. On the pet side, the anxiety medication Bonqat gained approval in China, while updated US labeling for Vanguard crLyme addressed subclinical arthritis. The acquisition of VitalRADS, a veterinary teleradiology platform, also closed, expanding the company's diagnostics capabilities globally.
Wall Street's Mixed Verdict
The analyst response has been swift but not uniformly bearish. William Blair downgraded the stock from Outperform to Market Perform, signaling that the growth narrative has taken a credibility hit. Piper Sandler's David Westenberg trimmed his price target from $90 to $80 while maintaining a Neutral stance, and Citigroup cut its target from $112 to $96 but held firm on Buy. BNP Paribas made the most dramatic adjustment, slashing its target from $146 to $110, yet retained its Outperform rating — a sign that some still see a medium-term recovery path.
The broader consensus has settled into a range of $80 to $115 across houses including JPMorgan, UBS, and Morgan Stanley, which had already lowered their targets in the days before the latest revisions. The direction is unambiguous, even if the conviction levels vary.
A CFO Transition at a Critical Juncture
Adding to the narrative is a leadership change that arrives precisely as the company navigates its most significant forecast reduction in recent memory. Jay Saccaro steps in as Executive Vice President, CFO, and COO on August 17, with outgoing finance chief Wetteny Joseph transitioning to a special advisor role to the CEO, supporting the handover into early 2027.
The Stock's Difficult Journey
The market's reaction has been severe. Shares currently trade around €65.06, roughly 5% above the 52-week low of €61.98 hit just recently, and about 2.6% below the 50-day moving average — evidence that the downward drift, while showing signs of stabilizing, hasn't reversed. The stock has lost approximately 12.6% since the guidance cut, and stands 39.81% lower year to date. At its August 2025 peak, the shares commanded €137.00; the current market capitalization of roughly €25.99 billion reflects how much ground has been lost.
A quarterly dividend of $0.53 per share is scheduled for September 1, payable to shareholders on record as of July 20 — a small measure of consistency for investors otherwise grappling with a turbulent stretch. Whether the livestock business can continue to serve as a stabilizing anchor while the pet segment and the C-suite both undergo their own resets remains the central question for the quarters ahead.
Ad
Zoetis Stock: New Analysis - 11 August
Fresh Zoetis information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
